| Assessment Status | Rapid Review Complete |
| HTA ID | 23050 |
| Drug | Nivolumab |
| Brand | Opdivo® |
| Indication | In combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable non-small cell lung cancer at high risk of recurrence in adult patients whose tumours have PD-L1 expression ≥ 1%. |
| Assessment Process | |
| Rapid review commissioned | 01/08/2023 |
| Rapid review completed | 17/08/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of nivolumab for this indication on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations. May 2024
